

**High-level Stakeholder Conference
Reducing Disparities Across the European Union**

**Wednesday, April 26th
09.00 – 17.30 CET
&
Thursday, April 27th
09.00 – 12.45 CET**

**Italian National Institute of Health
Viale Regina Elena, 299, 00161 Roma RM, Italy**

Background

There are many ways to refer to the subject of the High Level Conference that will address two flagships of the European Beating Cancer Plan which are '*Access and Diagnostics for All*' as well as '*Public Health Genomic*'. The discussions ahead will be centered around building an Open Innovation ecosystem for healthcare in Europe, through '*Access and Diagnostics for All*' as well as Public Health Genomics so as to facilitate bringing innovative medical interventions tailored to the specific needs of individual patients, thus providing better treatment and preventing undesirable adverse reactions while fostering a more efficient and cost-effective healthcare system.

The success of these two flagships starts with the stakeholders in particular the patients as well as the focus of the Cancer Mission Boards. It features big potential for improving the health of many patients and ensuring better outcomes of health systems efficiency and transparency. Yet, its integration into clinical practice and daily care is proving difficult given the many barriers and challenges to timely access to targeted healthcare that still exist as of today.

Health technology, health information and genomics are constantly evolving and have changed many aspects of patient care.

If '*Access and Diagnostics for all*' as well as Publics Health Genomics are to be in line with the EU principle of universal and equal access to high quality healthcare, then clearly it must be made available to many more citizens than it is now. What is requested is a long-term approach to innovation to ensure the translation of new therapies from laboratories to patients.

Recent initiatives in the UK and US, among other countries, have put this innovative method of diagnosing and treating patients in the spotlight while demonstrating that it is necessary to build frameworks that allow the delivery of the right treatment to the right patient at the right time, in accordance with the principle of equal and universal access to high quality health care. Incorporating patient perspectives into the regulatory process will help address their unmet medical needs

Moreover, in times of budgetary constraints, facilitating better-targeted and more cost-efficient treatment - to a potential 500 million patients in 28 EU Member States - is in line with the Europe 2020 strategy and the aims of the Juncker Commission.

The Von der Leyen Commission has made tackling cancer as one of its health policy priorities. At this event in Rome, By taking stock of what the stakeholders want and where we are in Europe in terms of access and diagnostics for all, acknowledging challenges need to be overcome. By



highlighting opportunities to accelerate progress, the scene for further action can be set. In this regard incentives on national and EU-level as well as cooperation between Member States are vital to make early access and public health genomics for patients throughout Europe a reality.

Expected outcomes

It is necessary to formulate a stakeholders centered strategy involving EU decision makers and regulators in the arena of public health, to enable EU and Member States to contribute to integrating health innovation into clinical practice while enabling much-greater access for patients for diagnostics, treatment as well as quality of life

In order to provide a clear focus and to devote sufficient space to analysis, discussions during the conference will concentrate on how:

- to assess and address obstacles to the integration of 'Access & Diagnostics for All' & Public Health Genomics' into Europe's healthcare systems
- to identify best practices and their added value
- to develop a guidance document to support funding so as to bring 'Access and Diagnostics for All' as well as Public Health genomics into healthcare systems
- to prepare a policy document that provides guidance to the European Commission regarding how the 13 Recommendation from the Cancer Mission can be implemented as well as ensuring that it is patient centric.

Participants

Attendees will be drawn from key stakeholders whose interaction will create a cross-sectoral, highly relevant and dynamic discussion forum. These participants will include public health decision makers, representatives from the Commission, Members of the European Parliament, patient organisations, and European umbrella organizations representing interest groups and associations actively engaged in the field. Each session will comprise panel discussions as well as Q&A sessions to allow best possible involvement of all participants.



Programme

08.30- 09:30: registration, coffee, networking

09:30- 09:40: Welcoming address by the

Marc Van den Bulcke, Project Coordinator, CanHeal. (*confirmed*)

Ruggero De Maria, *Presidente, Alleanza Contro il Cancro (confirmed)*

09:40- 10:10: Format of the Stakeholder Meeting and Policy Frameworks: The voice of the Stakeholders - A patient oriented healthcare as well as Public Health Genomics

Matthias Schuppe, *Project Team Leader for Cancer at DG Santé (confirmed) (10 Minutes)*

Francesco de Lorenzo, *ECPC President (confirmed)*

Denis Horgan, *EAPM Executive Director (confirmed)*

10:10- 11:00 Setting the Scene: Multistakeholder Discussion

Marco Marsella, *Head of Unit, eHealth, Well-being, and Ageing, DG Connect, European Commission (confirmed)*

Walter Ricciardi , *Chair of the EU Cancer Mission Professor of Hygiene and Public Health at Università Cattolica del Sacro Cuore, (confirmed)*

Dr Gaetano Guglielmi, *Deputy Director General for Health Research and Innovation, Italian. Ministry of Health.*

Stakeholder Conference moderator: **Denis Horgan**, Executive Director, European Alliance for Personalized Medicine

11:00 – 11:15: lunch

11:15-12:45: **Session 1: Tackling the Implementation Gap: SWOT**

Provide a Strength, Weakness, Opportunity and Threats of their respective area for the EU and national level.

- Strengths, which are the characteristics that can help achieve the desired outcome
- Weaknesses, which are organizational characteristics that may be harmful to achieving the outcome
- Opportunities, or the helpful conditions outside of the organization to achieve the outcome
- Threats, which are the harmful conditions outside of the organization to achieving the outcomes

Key Driver Projects

UNCAN: **Ruggero De Maria**, *Presidente, Alleanza Contro il Cancro (confirmed)*



EURACAN: **Jean-Yves Blay**, *Professor of Medicine at the University Claude Bernard, Lyon, France (10 minutes). (confirmed)*

AI: Synthema/GenoMed4All: **Gustavo Hernandez Peñaloza**, *Profesor Ayudante Doctor, Escuela Técnica Superior de Ingeniería de Sistemas Informáticos. (confirmed)*

CGI-Clinics: **Olivia Tort**, *PhD Project manager, “ CGI-Clinics, Institute for Research in Biomedicine (confirmed)*

Joint Action on Networks of Expertise: **Paolo G. Casali**, *Director of the Medical Oncology Unit 2 at the Istituto Nazionale Tumori, Milan, Italy (confirmed)*

HARMONY: **Guillermo Sanz**, *Head of Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain (confirmed)*

EuCanImage: **Karim Lekadir**, *Director of the Artificial Intelligence in Medicine Lab at the Universitat de Barcelona (BCN-AIM) and the Project Coordinator of EuCanImage. (confirmed)*

Q&A

12:45 – 13:45: lunch

13:45-15:15: Session 2: Public Private partnership & keeping the person in personalised healthcare

Provide a Strength, Weakness, Opportunity and Threats of their respective area for the EU and national level.

- Strengths, which are the characteristics that can help achieve the desired outcome)
- Weaknesses, which are organizational characteristics that may be harmful to achieving the outcome
- Opportunities, or the helpful conditions outside of the organization to achieve the outcome
- Threats, which are the harmful conditions outside of the organization to achieving the outcomes

Setting the Scene:

- **Dr. Carmen Laplaza Santos**, *Head of Unit, Health Innovations & Ecosystems, DG RTD, European Commission*

What lesson can be taken?

FairLife-Lung Cancer Care: **Torsten Gerriet Blum**, *Head of the Thoracic Oncology Assembly, European Respiratory Society (ERS) (confirmed)*

CAPABLE: **Manuel Ottaviano**, *Assistant Professor / Researcher / Project Manager Assistant Professor / Researcher / Project Manager, Universidad Politécnica de Madrid (Confirmed)*

LEGACy: **Tania Fleitas Kanonnikoff** *MD, PhD, Medical Oncology Department Hospital Clínico Universitario de Valencia Researcher Joan Rodés – INCLIVA. (confirmed)*



DIGICORE. **Gennaro Ciliberto**, *President, DIGICORE (10 minutes)*. (confirmed)

CanServ: **Jens Habermann**, *Director General of BBMRI-ERIC (confirmed)*

Innovator: MSD

Followed by Q&A.

15:15 -15:45: coffee break

15:45-17:20: Session III: Stakeholder feedback

Medical Oncology: **Rosa Giuliani**, *Medical Oncologist, Guy's and St Thomas' NHS Foundation Trust, London, UK*. (Confirmed)

Pathology: **Nicola Normanno**, *President of the International Quality Network for Pathology (IQN Path) (10 minutes (Confirmed)*

Innovator: **John Longshore**, *Head of Scientific Affairs for Global Oncology Diagnostics, AstraZeneca (10 minutes)*. (confirmed)

Public Health: **Stefania Boccia**, *professor of Hygiene and Public Health at the Università Cattolica del Sacro Cuore (UCSC), Rome, Italy (Confirmed)*

Respiratory: **Joanna Chorostowska-Wynimko**, *former Secretary General, European Respiratory Society (confirmed)*

Molecular Diagnostics: **Reinhard Buettner**, *Director of Department of Pathology, University Hospital Cologne, Köln (10 minute) (confirmed)*

Haemtology: **Giovanni Martinelli**, *Scientific Director, IRCCS Romagna Institute for the Study of Tumors "Dino Amadori" - IRST S.r.l. (confirmed)*

Human Genetics: **Maurizio Genuardi**, *Vice President, European Society of Human Genetics (confirmed)*

Feedback from Stakeholders (20 minutes)

Followed by Q&A.

17:20-17:30 – Summary of Day 1

Marc Van den Bulcke, *Project Coordinator, CanHeal (confirmed)*

D. Horgan, *EAPM Executive Director (confirmed)*

End of Day 1

Thursday, April 27th



09.00 – 12.00 CET

Day II

09:00- 09:15 – **Welcome to Day II**

- Welcome Back: **Marc Van den Bulcke**, Project Coordinator, CanHeal; **Denis Horgan**, WP Lead, EAPM Executive Director

09:15-11:00: **Session IV: Disease Use Cases,**

Rare Cancer: **Annalisa Trama**, Insituto Italiano Dei Tumouri. *(confirmed)*

Breast Cancer/Liquid Biopsy: **Giancarlo Troncione**, Full Professor, Anatomic pathology Public Health Department, University Federico 11, Naples, Italy. *(confirmed)*

Lung cancer: **Arsela Prelaj**, Principal Investigator and leader of the I3LUNG. *(confirmed)*

Pancreatic Cancer: **Núria Malats**, head of the Genetic and Molecular Epidemiology Group at the Spanish National Cancer Research Centre (CNIO), Madrid, Spain. *(confirmed)*

Ovarian Cancer: **Ettore D. Capoluongo**, Prof. of Clinical Biochemistry and Clinical Molecular Biology, Director of Clinical Pathology Department, Emergency Hospital "Cannizzaro" - Catania (Italy). *(confirmed)*

Pediatric Cancer: **Carmelo Rizzari**, SIOPE President (IT), University of Milano-Bicocca, Italy *(Confirmed)*

Sarcoma: **Iwona Lugowska**, Head of the Early Phase Clinical Trials Unit and Consultant in Oncology in the Department of Soft Tissue/Bone Sarcoma and Melanoma at the Maria Sklodowska-Curie National Institute and Oncology Centre (MSCI), Warsaw, Poland. *(Confirmed)*

Feedback from Stakeholders (20 minutes)

Followed by Q&A.

11:00 -11:15: coffee break

11:15-12:30: **Developing Priorities to support a policy roadmap: Stakeholder Feedback**

Oncology: **Josep Taberno**, Head of the Medical Oncology Department at the Vall d'Hebron Barcelona Hospital Campus, and Director of the Vall d'Hebron Institute of Oncology (VHIO).

IEO: **Gabriella Pravettoni**, Director, Applied Research Division for Cognitive and Psychological Science, European Institute of Oncology *(confirmed)*

Innovator: **Ivana Cattaneo**, Executive Director, Oncology Policy & Healthcare Systems, Novartis Europe *(confirmed)*

Cancer Mission Hubs: Networks and Synergies: **Anabela Isidro**, Member of the Board · AICIB - Agência de Investigação Clínica e Inovação Biomédical. *(confirmed)*

Feedback for Action from the WP leads of CanHeal

12:30-12:45: **End of Meeting and thanks from PC:**





Marc Van den Bulcke, Project Coordinator, CanHeal. (3 Minutes) *(confirmed)*

Francesco de Lorenzo, ECPC President *(confirmed)*

D. Horgan, EAPM Executive Director *(confirmed)*

12:45 – 13.30: lunch

CanHeal AGM

April 27 @13.30

